C. Schlichting
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
Papers in
- Oncology 9
- Colorectal Cancer Treatments and Studies 7
- Cancer Treatment and Pharmacology 5
-
- Immunotherapy and Immune Responses 5
- T-cell and B-cell Immunology 3
- Atherosclerosis and Cardiovascular Diseases 2
- Co-authors
- Michael Weis (7 shared papers)Eric Van Cutsem (2 shared papers)Christophe Borg (2 shared papers)Jaafar Bennouna (2 shared papers)Richard Greil (3 shared papers)Claus-Christoph Steffens (2 shared papers)Olivier Bouché (2 shared papers)Vicente Alonso-Orduña (2 shared papers)
In The Last Decade
C. Schlichting
16 papers receiving 1.1k citations
C. Schlichting's Hit Papers
Peers
Comparison fields: 5 of 74
- Hepatology 297
- Oncology 822
- Pulmonary and Respiratory Medicine 405
- Transplantation 24
- Cancer Research 128
Countries citing papers authored by C. Schlichting
This map shows the geographic impact of C. Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Schlichting more than expected).
Fields of papers citing papers by C. Schlichting
This network shows the impact of papers produced by C. Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Schlichting. The network helps show where C. Schlichting may publish in the future.
Co-authors
The 25 scholars most cited alongside C. Schlichting, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Hit paper breakdown → | 2012 | 829 |
| 2 | 2002 | 88 | |
| 3 | 2003 | 52 | |
| 4 | 2006 | 38 | |
| 5 | 2006 | 37 | |
| 6 | 2004 | 33 | |
| 7 | 2007 | 19 | |
| 8 | 2001 | 17 | |
| 9 | 2005 | 11 | |
| 10 | 2005 | 8 | |
| 11 | 2007 | 7 | |
| 12 | 2004 | 6 | |
| 13 | 2005 | 4 | |
| 14 | 2004 | 3 | |
| 15 | 2012 | 2 | |
| 16 | 2013 | 1 |
About C. Schlichting
C. Schlichting is a scholar working on Oncology, Immunology, Immunology and Allergy, Surgery and Pulmonary and Respiratory Medicine, having authored 16 papers that have together received 1.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (5 papers), Immunotherapy and Immune Responses (5 papers), Cell Adhesion Molecules Research (3 papers), T-cell and B-cell Immunology (3 papers), Atherosclerosis and Cardiovascular Diseases (2 papers), Renal Transplantation Outcomes and Treatments (2 papers) and Organ Transplantation Techniques and Outcomes (2 papers). The work is most often cited by research in Hepatology (297 citations), Oncology (822 citations), Pulmonary and Respiratory Medicine (405 citations), Transplantation (24 citations) and Cancer Research (128 citations). C. Schlichting has collaborated with scholars based in Germany, Finland and Spain. Frequent co-authors include Michael Weis, Eric Van Cutsem, Christophe Borg, Jaafar Bennouna, Richard Greil, Claus-Christoph Steffens, Olivier Bouché, Vicente Alonso-Orduña, Pia Österlund and José María Viéitez. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Mini-Reviews in Medicinal Chemistry, Journal of Cardiovascular Pharmacology and Regulatory Toxicology and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.